GlassScriptPhysician profile
Aamir Iqbal
NPI 1053327171
$4,340.29
in general payments reported to CMS, 2019-2025
23 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $60.44 · 2021: $292 · 2022: $626 · 2023: $747 · 2024: $1,214 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221 · Education: $30.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.06 |
| Education | $30.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,047.46 | 2021-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $468.25 | 2021-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $357.38 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $329.11 | 2021-2025 | Tavneos, Aranesp, Parsabiv |
| Calliditas Therapeutics US INC. | $289.16 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $268.96 | 2021-2025 | |
| Travere Therapeutics, INC. | $254.52 | 2024-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $197.89 | 2020-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $197.41 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $171.38 | 2020-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $146.25 | 2023-2025 | |
| Glaxosmithkline, LLC. | $103.00 | 2021-2024 | Benlysta |
| Mallinckrodt Enterprises LLC | $83.15 | 2019 | |
| Novo Nordisk INC | $68.96 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.70 | 2024-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $65.27 | 2025 | |
| Horizon Therapeutics Plc | $58.39 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $57.94 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $34.35 | 2022-2024 | Velphoro |
| Shield Therapeutics INC | $31.82 | 2023-2025 | Accrufer |
| Akebia Therapeutics INC | $16.82 | 2025 | Vafseo |
| Allergan, INC. | $12.73 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.